Drug Trial Radar · NCT06578507
Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jan 21, 2025
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- TheraviaIndustry
- Sponsor type
- Industry
- First posted
- Aug 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 9 months, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months
Conditions
- Sickle Cell Disease
Interventions
HydroxycarbamidDrug
Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide. The IMP will be administered as half-strength twice daily, based on the body weight of the patient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through area under the curve (AUC)Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
- Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through time to obtain the maximum concentration (Tmax)Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
- Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through maximum plasma concentration (Cmax)Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Centre Hospitalier Intercommunal Créteil
Créteil, France · Recruiting
GHEF- Site de Marne-la-Vallée
Jossigny, France · Recruiting
Hôpital Bicêtre
Le Kremlin-Bicêtre, France · Recruiting
Institut d'Hématologie et d'oncologie pédiatrique - IHOPe
Lyon, France · Suspended
Hôpital Necker-Enfants malades
Paris, France · Recruiting
CH Saint-Denis
Saint-Denis, France · Recruiting
Centre hospitalier de Cayenne
Cayenne, French Guiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.